Volume | 56,005 |
|
|||||
News | - | ||||||
Day High | 4.631 | Low High |
|||||
Day Low | 4.12 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NeuroBo Pharmaceuticals Inc | NRBO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.28 | 4.12 | 4.631 | 4.60 | 4.24 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
331 | 56,005 | $ 4.40 | $ 246,637 | - | 2.8888 - 6.7499 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:12:13 | 11 | $ 4.50 | USD |
NeuroBo Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
22.32M | 4.85M | - | 0 | -12.47M | -2.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NeuroBo Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRBO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.88 | 4.631 | 3.85 | 4.05 | 16,656 | 0.57 | 14.69% |
1 Month | 3.63 | 4.631 | 2.99 | 3.55 | 23,613 | 0.82 | 22.59% |
3 Months | 5.86 | 6.7499 | 2.99 | 5.35 | 110,506 | -1.41 | -24.06% |
6 Months | 3.3624 | 6.7499 | 2.90 | 5.33 | 710,918 | 1.09 | 32.35% |
1 Year | 4.6256 | 6.7499 | 2.8888 | 5.00 | 470,849 | -0.1756 | -3.80% |
3 Years | 688.80 | 1,576.80 | 2.8888 | 259.72 | 1,036,996 | -684.35 | -99.35% |
5 Years | 2,196.00 | 7,200.00 | 2.8888 | 321.61 | 744,115 | -2,191.55 | -99.80% |
NeuroBo Pharmaceuticals Description
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. |